Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T.

Cancer Sci. 2019 Feb 11. doi: 10.1111/cas.13969. [Epub ahead of print]

2.

Regio- and Enantioselective Intramolecular Amide Carbene Insertion into Primary C-H Bonds Using Ru(II)-Pheox Catalyst.

Nakagawa Y, Chanthamath S, Liang Y, Shibatomi K, Iwasa S.

J Org Chem. 2019 Feb 12. doi: 10.1021/acs.joc.8b03044. [Epub ahead of print]

PMID:
30703331
3.

Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer.

Yamaguchi T, Iwasa S, Shoji H, Honma Y, Takashima A, Kato K, Hamaguchi T, Higuchi K, Boku N.

Gastric Cancer. 2019 Jan 2. doi: 10.1007/s10120-018-00917-5. [Epub ahead of print]

PMID:
30603911
4.

Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors.

Ando Y, Iwasa S, Takahashi S, Saka H, Kakizume T, Natsume K, Suenaga N, Quadt C, Yamada Y.

Cancer Sci. 2018 Dec 26. doi: 10.1111/cas.13923. [Epub ahead of print]

5.

Effect of hypoxia on the expression of CCAAT/enhancer-binding protein β and receptor activator of nuclear factor kappa-B ligand in periodontal ligament cells.

Ito H, Kifune T, Ishiyama M, Iwasa S, Takei H, Hasegawa T, Asano M, Shirakawa T.

J Oral Sci. 2018;60(4):544-551. doi: 10.2334/josnusd.17-0436.

6.

Hypoxia-induced upregulation of angiogenic factors in immortalized human periodontal ligament fibroblasts.

Kifune T, Ito H, Ishiyama M, Iwasa S, Takei H, Hasegawa T, Asano M, Shirakawa T.

J Oral Sci. 2018;60(4):519-525. doi: 10.2334/josnusd.17-0441.

7.

Computational chemical analysis of Ru(II)-Pheox-catalyzed highly enantioselective intramolecular cyclopropanation reactions.

Nakagawa Y, Nakayama N, Goto H, Fujisawa I, Chanthamath S, Shibatomi K, Iwasa S.

Chirality. 2019 Jan;31(1):52-61. doi: 10.1002/chir.23033. Epub 2018 Dec 4.

PMID:
30515897
8.

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.

Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, Nishina T, Hara H, Machida N, Komatsu Y, Shimada Y, Otsu S, Shimizu S, Watanabe M.

Gastric Cancer. 2018 Dec 4. doi: 10.1007/s10120-018-0903-1. [Epub ahead of print]

PMID:
30515672
9.

Development of Enzyme-Linked Immunosorbent Assay for Analysis of Total Aflatoxins Based on Monoclonal Antibody Reactive with Aflatoxins B1, B2, G1 and G2.

Yamasaki T, Miyake S, Sato N, Hirakawa Y, Iwasa S, Narita H, Watanabe T.

Shokuhin Eiseigaku Zasshi. 2018;59(5):200-205. doi: 10.3358/shokueishi.59.200.

10.

Maternal Acrylamide Intake during Pregnancy and Sex Hormone Levels in Maternal and Umbilical Cord Blood and Birth Size of Offspring.

Nagata C, Konishi K, Wada K, Tamura T, Goto Y, Koda S, Mizuta F, Iwasa S.

Nutr Cancer. 2018 Nov 14:1-6. doi: 10.1080/01635581.2018.1524018. [Epub ahead of print]

PMID:
30426779
11.

Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.

Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N.

Invest New Drugs. 2018 Sep 28. doi: 10.1007/s10637-018-0669-7. [Epub ahead of print]

PMID:
30267338
12.
13.

Skin-derived precursor cells undergo substrate-dependent galvanotaxis that can be modified by neighbouring cells.

Iwasa SN, Popovic MR, Morshead CM.

Stem Cell Res. 2018 Aug;31:95-101. doi: 10.1016/j.scr.2018.07.019. Epub 2018 Jul 19.

14.

Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.

Iwasa S, Yamamoto N, Shitara K, Tamura K, Matsubara N, Tajimi M, Lin AB, Asou H, Cai Z, Inoue K, Shibasaki Y, Saito K, Takai H, Doi T.

Cancer Sci. 2018 Oct;109(10):3216-3223. doi: 10.1111/cas.13750.

15.

Retrospective Analyses of Systemic Chemotherapy and Cytoreductive Surgery for Patients with Ovarian Metastases from Colorectal Cancer: A Single-Center Experience.

Sekine K, Hamaguchi T, Shoji H, Takashima A, Honma Y, Iwasa S, Kato K, Takahashi K, Kato T, Kanemitsu Y, Boku N.

Oncology. 2018;95(4):220-228. doi: 10.1159/000489665. Epub 2018 Jul 20.

PMID:
30032147
16.

Direct Catalytic Asymmetric Cyclopropylphosphonation Reactions of N,N-Dialkyl Groups of Aniline Derivatives by Ru(II)-Pheox Complex.

Le CTL, Ozaki S, Chanthamath S, Shibatomi K, Iwasa S.

Org Lett. 2018 Aug 3;20(15):4490-4494. doi: 10.1021/acs.orglett.8b01788. Epub 2018 Jul 11.

PMID:
29992821
17.

Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study.

Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Shimada Y, Yamada Y.

Br J Radiol. 2018 Sep;91(1089):20180259. doi: 10.1259/bjr.20180259. Epub 2018 Jun 27.

PMID:
29916721
18.

Development of an Immunosensor Based on Surface Plasmon Resonance for Simultaneous Residue Analysis of Three Pesticides -Boscalid, Clothianidin, and Nitenpyram- in Vegetables.

Hirakawa Y, Yamasaki T, Harada A, Iwasa S, Narita H, Miyake S.

Anal Sci. 2018;34(5):533-539. doi: 10.2116/analsci.17P487.

19.

Highly enantioselective synthesis of trifluoromethyl cyclopropanes by using Ru(ii)-Pheox catalysts.

Kotozaki M, Chanthamath S, Fujii T, Shibatomi K, Iwasa S.

Chem Commun (Camb). 2018 May 15;54(40):5110-5113. doi: 10.1039/c8cc02286k.

PMID:
29717307
20.

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.

Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW.

Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16.

PMID:
29555258
21.

Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma.

Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Ito Y, Itami J, Boku N, Higuchi K.

Int J Clin Oncol. 2018 Aug;23(4):652-658. doi: 10.1007/s10147-018-1258-7. Epub 2018 Mar 8.

PMID:
29520523
22.

A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.

Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N.

Int J Clin Oncol. 2018 Jun;23(3):466-472. doi: 10.1007/s10147-018-1239-x. Epub 2018 Jan 20.

PMID:
29353337
23.

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.

Kato K, Ura T, Koizumi W, Iwasa S, Katada C, Azuma M, Ishikura S, Nakao Y, Onuma H, Muro K.

Cancer Sci. 2018 Mar;109(3):785-793. doi: 10.1111/cas.13481. Epub 2018 Feb 15.

24.

The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy.

Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y, Hamaguchi T.

Oncotarget. 2017 May 30;8(56):95083-95094. doi: 10.18632/oncotarget.18297. eCollection 2017 Nov 10.

25.

A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).

Akiyoshi K, Hamaguchi T, Yoshimura K, Takahashi N, Honma Y, Iwasa S, Takashima A, Kato K, Yamada Y, Onodera H, Takeshita S, Yasui H, Sakai G, Akatsuka S, Ogawa K, Horita Y, Nagai Y, Shimada Y.

Clin Colorectal Cancer. 2018 Mar;17(1):e83-e89. doi: 10.1016/j.clcc.2017.10.004. Epub 2017 Oct 16.

PMID:
29169974
26.

Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma.

Sudo K, Kato K, Kuwabara H, Sasaki Y, Takahashi N, Shoji H, Iwasa S, Honma Y, Okita NT, Takashima A, Hamaguchi T, Yamada Y, Ito Y, Itami J, Fukuda T, Tobinai K, Boku N.

Oncology. 2018;94(1):47-54. doi: 10.1159/000480515. Epub 2017 Oct 28.

PMID:
29080886
27.

Highly stereoselective cyclopropanation of various olefins with diazosulfones catalyzed by Ru(ii)-Pheox complexes.

Kotozaki M, Chanthamath S, Fujisawa I, Shibatomi K, Iwasa S.

Chem Commun (Camb). 2017 Nov 9;53(90):12193-12196. doi: 10.1039/c7cc05951e.

PMID:
29072719
28.

Synthesis, Crystal Structure, and Photoluminescent Properties of 3,3',4,4'-Tetraethyl-5,5'-divinyl-2,2'-bipyrrole Derivatives.

Okawara T, Kawano R, Morita H, Finkelstein A, Toyofuku R, Matsumoto K, Takehara K, Nagamura T, Iwasa S, Kumar S.

Molecules. 2017 Oct 26;22(11). pii: E1816. doi: 10.3390/molecules22111816.

29.

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.

Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N.

Int J Clin Oncol. 2018 Apr;23(2):382-388. doi: 10.1007/s10147-017-1200-4. Epub 2017 Oct 16.

PMID:
29039073
30.

Abstracts and Workshops 7th National Spinal Cord Injury Conference November 9 - 11, 2017 Fallsview Casino Resort Niagara Falls, Ontario, Canada.

Shojaei MH, Alavinia M, Craven BC, Cheng CL, Plashkes T, Shen T, Fallah N, Humphreys S, O'Connell C, Linassi AG, Ho C, Short C, Ethans K, Charbonneau R, Paquet J, Noonan VK, Furlan JC, Fehlings MG, Craven BC, Likitlersuang J, Sumitro E, Kalsi-Ryan S, Zariffa J, Wolfe D, Cornell S, Gagliardi J, Marrocco S, Rivers CS, Fallah NN, Noonan VK, Whitehurst D, Schwartz C, Finkelstein J, Craven BC, Ethans K, O'Connell C, Truchon C, Ho C, Linassi AG, Short C, Tsai E, Drew B, Ahn H, Dvorak MF, Paquet J, Fehlings MG, Noreau L, Lenz K, Bailey KA, Allison D, Ditor D, Baron J, Tomasone J, Curran D, Miller T, Grimshaw J, Moineau B, Alizadeh-Meghrazi M, Stefan G, Masani K, Popovic MR, Sumitro E, Likitlersuang J, Kalsi-Ryan S, Zariffa J, Garcia-Garcia MG, Marquez-Chin C, Popovic MR, Furlan JC, Gulasingam S, Craven BC, Furlan JC, Gulasingam S, Craven BC, Khan A, Pujol C, Laylor M, Unic N, Pakosh M, Musselman K, Brisbois LM, Catharine Craven B, Verrier MC, Jones MK, O'Shea R, Valika S, Holtz K, Szefer E, Noonan V, Kwon B, Mills P, Morin C, Harris A, Cheng C, Aspinall A, Plashkes T, Noonan VK, Chan K, Verrier MC, Craven BC, Alappat C, Flett HM, Furlan JC, Musselman KE, Milligan J, Hillier LM, Bauman C, Donaldson L, Lee J, Milligan J, Lee J, Hillier LM, Slonim K, Wolfe D, Sleeth L, Jeske S, Kras-Dupuis A, Marrocco S, McRae S, Flett H, Mokry J, Zee J, Bayley M, Lemay JF, Roy A, Gagnon HD, Jones MK, O'Shea R, Theiss R, Flett H, Guy K, Johnston G, Kokotow M, Mills S, Mokry J, Bain P, Scovil C, Houghton P, Lala D, Orr L, Holyoke P, Wolfe D, Orr L, Brooke J, Holyoke P, Lala D, Houghton P, Martin Ginis KA, Shaw RB, Stork MJ, McBride CB, Furlan JC, Craven BC, Giangregorio L, Hitzig S, Kapadia N, Popovic MR, Zivanovic V, Valiante T, Popovic MR, Patsakos E, Brisbois L, Farahani F, Kaiser A, Craven BC, Patsakos E, Kaiser A, Brisbois L, Farahani F, Craven BC, Mortenson B, MacGillivray M, Mahsa S, Adams J, Sawatzky B, Mills P, Arbour-Nicitopoulos K, Bassett-Gunter R, Leo J, Sharma R, Latimer-Cheung A, Olds T, Martin Ginis K, Graco M, Cross S, Thiyagarajan C, Shafazand S, Ayas N, Schembri R, Booker L, Nicholls C, Burns P, Nash M, Green S, Berlowitz DJ, Taran S, Rocchi M, Martin Ginis KA, Sweet SN, Caron JG, Sweet SN, Rocchi MA, Zelaya W, Sweet SN, Bergquist AJ, Del Castillo-Valenzuela MF, Popovic MR, Masani K, Ethans K, Casey A, Namaka M, Krassiokov-Enns D, Marquez-Chin C, Marquis A, Desai N, Zivanovic V, Hebert D, Popovic MR, Furlan JC, Craven BC, McLeod J, Hicks A, Gauthier C, Arel J, Brosseau R, Hicks AL, Gagnon DH, Nejatbakhsh N, Kaiser A, Hitzig SL, Cappe S, McGillivray C, Singh H, Sam J, Flett H, Craven BC, Verrier M, Musselman K, Koh RGL, Garai P, Zariffa J, Unger J, Oates AR, Arora T, Musselman K, Moshe B, Anthony B, Gulasingam S, Craven BC, Michalovic E, Gainforth HL, Baron J, Graham ID, Sweet SN, Chan B, Craven BC, Wodchis W, Cadarette S, Krahn M, Mittmann N, Chemtob K, Rocchi MA, Arbour-Nicitopoulos K, Kairy D, Sweet SN, Sabetian P, Koh RGL, Zariffa J, Yoo P, Iwasa SN, Babona-Pilipos R, Schneider P, Velayudhan P, Ahmed U, Popovic MR, Morshead CM, Yoo J, Shinya M, Milosevic M, Masani K, Gabison S, Mathur S, Nussbaum E, Popovic M, Verrier MC, Musselman K, Lemay JF, McCullum S, Guy K, Walden K, Zariffa J, Kalsi-Ryan S, Alizadeh-Meghrazi M, Lee J, Milligan J, Smith M, Athanasopoulos P, Jeji T, Howcroft J, Howcroft J, Townson A, Willms R, Plashkes T, Mills S, Flett H, Scovil C, Mazzella F, Morris H, Ventre A, Loh E, Guy S, Kramer J, Jeji T, Xia N, Mehta S, Martin Ginis KA, McBride CB, Shaw RB, West C, Ethans K, O'Connell C, Charlifue S, Gagnon DH, Escalona Castillo MJ, Vermette M, Carvalho LP, Karelis A, Kairy D, Aubertin-Leheudre M, Duclos C, Houghton PE, Orr L, Holyoke P, Kras-Dupuis A, Wolfe D, Munro B, Sweeny M, Craven BC, Flett H, Hitzig S, Farahani F, Alavinia SM, Omidvar M, Bayley M, Sweet SN, Gassaway J, Shaw R, Hong M, Everhart-Skeels S, Houlihan B, Burns A, Bilsky G, Lanig I, Graco M, Cross S, Thiyagarajan C, Shafazand S, Ayas N, Schembri R, Booker L, Nicholls C, Burns P, Nash M, Green S, Berlowitz D, Furlan JC, Kalsi-Ryan S.

J Spinal Cord Med. 2017 Nov;40(6):813-869. doi: 10.1080/10790268.2017.1369666. No abstract available.

31.

Atypical femoral fracture associated with bone-modifying agent for bone metastasis of breast cancer: A report of two cases.

Tateiwa D, Outani H, Iwasa S, Imura Y, Tanaka T, Oshima K, Naka N, Araki N.

J Orthop Surg (Hong Kong). 2017 Sep-Dec;25(3):2309499017727916. doi: 10.1177/2309499017727916.

PMID:
28844196
32.

A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.

Sasaki Y, Iwasa S, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Nagai Y, Hirano H, Honma Y, Takashima A, Kato K, Hamaguchi T.

Gastric Cancer. 2018 May;21(3):439-445. doi: 10.1007/s10120-017-0753-2. Epub 2017 Aug 1.

PMID:
28766263
33.

Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent.

Honma Y, Hokamura N, Nagashima K, Sudo K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Umezawa R, Ito Y, Itami J, Koyanagi K, Igaki H, Tachimori Y.

Anticancer Res. 2017 Jul;37(7):3741-3749.

PMID:
28668869
34.

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature.

Watanabe S, Takashima A, Taniguchi H, Tanaka Y, Nakamura S, Okita N, Honma Y, Iwasa S, Kato K, Hamaguchi T, Boku N.

Case Rep Oncol. 2017 May 5;10(2):407-415. doi: 10.1159/000474939. eCollection 2017 May-Aug.

35.

Environmental Factors That Influence Stem Cell Migration: An "Electric Field".

Iwasa SN, Babona-Pilipos R, Morshead CM.

Stem Cells Int. 2017;2017:4276927. doi: 10.1155/2017/4276927. Epub 2017 May 15. Review.

36.

Enantioselective decarboxylative chlorination of β-ketocarboxylic acids.

Shibatomi K, Kitahara K, Sasaki N, Kawasaki Y, Fujisawa I, Iwasa S.

Nat Commun. 2017 Jun 5;8:15600. doi: 10.1038/ncomms15600.

37.

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.

Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Kitagawa Y.

Lancet Oncol. 2017 May;18(5):631-639. doi: 10.1016/S1470-2045(17)30181-X. Epub 2017 Mar 15.

PMID:
28314688
38.

Ru(ii)-Pheox-catalyzed Si-H insertion reaction: construction of enantioenriched carbon and silicon centers.

Nakagawa Y, Chanthamath S, Fujisawa I, Shibatomi K, Iwasa S.

Chem Commun (Camb). 2017 Mar 28;53(26):3753-3756. doi: 10.1039/c7cc01070b.

PMID:
28304026
39.

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.

Shimomura A, Kondo S, Kobayashi N, Iwasa S, Kitano S, Tamura K, Fujiwara Y, Yamamoto N.

Int J Clin Oncol. 2017 Aug;22(4):780-785. doi: 10.1007/s10147-017-1108-z. Epub 2017 Mar 14.

40.

[Comparison of Response to Chemotherapy between Ovarian and Extraovarian Metastasis of Gastric Cancer].

Ishimoto U, Nakamura S, Sasaki Y, Takahashi N, Iwasa S, Honma Y, Okita N, Takashima A, Kato K, Hamaguchi T, Boku N.

Gan To Kagaku Ryoho. 2017 Mar;44(3):233-237. Japanese.

PMID:
28292993
41.

Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.

Taniguchi H, Iwasa S, Yamazaki K, Yoshino T, Kiryu C, Naka Y, Liew EL, Sakata Y.

Cancer Sci. 2017 May;108(5):1013-1021. doi: 10.1111/cas.13227. Epub 2017 May 11.

42.

NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis.

Doi T, Hamaguchi T, Shitara K, Iwasa S, Shimada Y, Harada M, Naito K, Hayashi N, Masada A, Ohtsu A.

Cancer Chemother Pharmacol. 2017 Mar;79(3):569-578. doi: 10.1007/s00280-017-3254-4. Epub 2017 Feb 21.

43.

Immature Core protein of hepatitis C virus induces an unfolded protein response through inhibition of ERAD-L in a yeast model system.

Takahashi S, Sato N, Kikuchi J, Kakinuma H, Okawa J, Masuyama Y, Iwasa S, Irokawa H, Hwang GW, Naganuma A, Kohara M, Kuge S.

Genes Cells. 2017 Feb;22(2):160-173. doi: 10.1111/gtc.12464. Epub 2017 Jan 18.

44.

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.

Saka H, Kitagawa C, Kogure Y, Takahashi Y, Fujikawa K, Sagawa T, Iwasa S, Takahashi N, Fukao T, Tchinou C, Landers D, Yamada Y.

Invest New Drugs. 2017 Aug;35(4):451-462. doi: 10.1007/s10637-016-0416-x. Epub 2017 Jan 10.

45.

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.

Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H, Yamazaki K, Han SW, Wang W, Ahn JB, Deng Y, Cho SH, Ba Y, Lee KW, Zhang T, Satoh T, Buyse ME, Ryoo BY, Shen L, Sakamoto J, Kim TW.

Chin J Cancer. 2016 Dec 22;35(1):102. doi: 10.1186/s40880-016-0166-3.

46.

Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.

Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Boku N.

Gastric Cancer. 2017 Jul;20(4):655-662. doi: 10.1007/s10120-016-0670-9. Epub 2016 Nov 17.

PMID:
27858180
47.

Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials.

Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, Iwasa S, Ochiai A, Yamamoto N, Fujiwara Y, Tamura K.

Mol Cancer. 2016 Nov 16;15(1):73.

48.

Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane.

Nomura M, Iwasa S, Tsushima T, Kato K, Yasui H, Boku N, Muto M, Muro K.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1209-1216. doi: 10.1007/s00280-016-3179-3. Epub 2016 Oct 24.

PMID:
27778070
49.

Enantioselective Cyclopropanation of a Wide Variety of Olefins Catalyzed by Ru(II)-Pheox Complexes.

Chanthamath S, Iwasa S.

Acc Chem Res. 2016 Oct 18;49(10):2080-2090. Epub 2016 Sep 20.

PMID:
27648664
50.

Functional expression of TLR5 in murine salivary gland epithelial cells.

Iwasa S, Ota H, Nishio K, Ohtsu M, Kusunoki M, Gojoubori T, Shirakawa T, Asano M.

J Oral Sci. 2016;58(3):317-23. doi: 10.2334/josnusd.15-0588.

Supplemental Content

Support Center